Sponsors
The bill aims to lower prescription drug list prices and increase pricing transparency to reduce costs for patients and public programs, but it risks reduced U.S. availability of some medicines, shifted costs or reduced innovation, and significant enforcement complexity.
Patients (insured and uninsured), Medicare and Medicaid beneficiaries, and other purchasers would likely pay lower U.S. list prices for covered prescription drugs because prices are capped at the average of six high‑income countries, lowering out‑of‑pocket costs and reducing public program spending.
Taxpayers, regulators, and patients would gain greater price transparency from required annual manufacturer reporting, making it easier to compare U.S. and international prices and inform policy and purchasing decisions.
Patients with chronic conditions and health systems could face reduced or delayed access if manufacturers limit U.S. launches or withdraw high‑priced medicines in response to the price cap.
Taxpayers and patients could suffer if manufacturers respond by raising prices on other drugs, shifting costs to non‑covered products, or cutting R&D investment, potentially slowing new drug development.
Taxpayers and federal agencies could face large administrative and fiscal burdens because the civil penalty (ten times the per‑unit price difference) may produce very large fines and complex enforcement requirements for HHS.
Based on analysis of 2 sections of legislative text.
Caps U.S. retail list prices for covered drugs and biologics at the annual average list price across six foreign countries and imposes penalties if manufacturers exceed that cap.
Introduced May 13, 2025 by Jefferson Van Drew · Last progress May 13, 2025
Requires the HHS Secretary to cap the U.S. retail list price of covered prescription drugs and biological products so that it does not exceed the annual average retail list price for the same product across Canada, France, Germany, Italy, Japan, and the United Kingdom. Manufacturers must report U.S. and those foreign list prices each year, and manufacturers who sell above the cap must pay a civil monetary penalty equal to ten times the per-unit difference for each unit sold above the cap.